Dedicated High-Performance Breast PET/CT

专用高性能乳房 PET/CT

• 批准号: 7844895
• 负责人: RAMSEY D. BADAWI
• 金额: $ 70.5万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-15 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7844895
• 关键词: 3-Dimensional; Address; Anatomy; Area; Arts; Axilla; Behavior; Benchmarking; Biological Models; Biopsy; Blood Vessels; Breast; Breast Cancer Treatment; Cancer Patient; Characteristics; Chest wall structure; Clinic; Clinical; Communities; Computer software; Data; Detection; Devices; Disease; Drops; Electronics; Ensure; Health; Histology; Human; Hybrids; Image; Imaging Device; Label; Life; Low Dose Radiation; Magnetic Resonance Imaging; Malignant Neoplasms; Mammary Gland Parenchyma; Mammography; Mastectomy; Measurement; Measures; Metabolic; Methodology; Methods; Modeling; Molecular; Newly Diagnosed; Noise; Nuclear; Operating System; Operative Surgical Procedures; Output; PET/CT scan; Patient Care; Patients; Performance; Pharmaceutical Preparations; Phase; Play; Population; Positioning Attribute; Positron-Emission Tomography; Predictive Value; Problem Solving; Process; Radioisotopes; Reading; Reporting; Research Infrastructure; Research Personnel; Resolution; Role; Scheme; Source; Staging; Staining method; Stains; System; Techniques; Technology; Testing; Therapeutic; Three-Dimensional Image; Time; Tissues; Tracer; Translating; Translations; Tube; Validation; Woman; Work; analog; attenuation; base; clinical efficacy; cost; data acquisition; design; detector; drug development; follow-up; image reconstruction; imaging modality; improved; in vivo; malignant breast neoplasm; molecular imaging; mortality; novel; performance tests; photomultiplier; prototype; public health relevance; reconstruction; response; scale up; simulation; therapy development; tool

DESCRIPTION (provided by applicant): Objectives: To build a high-performance, high-resolution quantitative PET/CT scanner dedicated to imaging the breast. This will permit validation of anato-metabolic imaging of the breast in the contexts of local staging, prediction of therapeutic response, follow-up for patients receiving conservative therapy and the development of new drugs for breast cancer treatment. Methods: Using a novel high-resolution, low-dead-time scintillation detector design using a dual-ended read-out scheme using APDs and PSPMTs, and a modified version of commercial PET electronics, we will build a PET scanner compact enough to fit inside the gantry of our existing breast CT scanner. We will combine the two devices to allow sequential imaging of the breast in the same clinical setting, resulting in accurately registered high-resolution functional and anatomic images. The device will be compatible with biopsy tools and will be expandable to facilitate imaging of the chest wall and axillae. Construction will be phased. At each stage we will use a continuous test/re-test approach using pre-calculated bench-marks to permit efficient and timely resolution of arising issues. We will employ state-of-the-art image reconstruction techniques using measured system models to maximize spatial resolution, and we will carefully implement all necessary data corrections for quantitative imaging. We will compare performance with whole-body PET/CT and MRI in a trial of 30 patients with known breast cancer. Health relatedness: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care. PUBLIC HEALTH RELEVANCE: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care.

描述（由申请人提供）：目的：构建一种专用于乳腺成像的高性能、高分辨率定量PET/CT扫描仪。这将允许在局部分期、治疗反应预测、接受保守治疗的患者的随访和乳腺癌治疗新药的开发的背景下验证乳房的解剖代谢成像。研究方法：使用一种新颖的高分辨率，低死区时间闪烁探测器设计，使用APD和PSPMT的双端读出方案，以及商业PET电子设备的修改版本，我们将构建一个PET扫描仪，其足够紧凑，可以安装在我们现有的乳腺CT扫描仪的机架内。我们将联合收割机与这两种器械结合使用，以便在相同的临床环境中对乳房进行连续成像，从而获得准确配准的高分辨率功能和解剖图像。该器械将与活检工具兼容，并可扩展以便于胸壁和腋窝成像。建设将分阶段进行。在每个阶段，我们将使用预先计算的基准点进行连续测试/重新测试，以高效、及时地解决出现的问题。我们将采用最先进的图像重建技术，使用测量的系统模型，以最大限度地提高空间分辨率，我们将仔细实施所有必要的数据校正定量成像。我们将在30例已知乳腺癌患者的试验中比较全身PET/CT和MRI的性能。健康相关性：到目前为止，在临床上测试的乳腺PET成像仪是低成本、低性能的设备，不能充分评估体内方法，并且不能提供与3D解剖信息融合的3D图像（一种在体内得到充分证明的技术）。因此，分子成像在分期和再分期、对治疗研究的反应和药物开发中的已知能力对于大部分患有原发性乳腺癌的女性是不可用的。申报器械将解决这一问题，并允许确定充分临床性能的最低成像要求-将该技术转化为患者护理的先决条件。公共卫生相关性：到目前为止，在临床上测试的乳腺PET成像仪是低成本、低性能的设备，不能充分评估体内方法，并且不能提供与3D解剖信息融合的3D图像（一种在体内得到充分证明的技术）。因此，分子成像在分期和再分期、对治疗研究的反应和药物开发中的已知能力对于大部分患有原发性乳腺癌的女性是不可用的。申报器械将解决这一问题，并允许确定充分临床性能的最低成像要求-将该技术转化为患者护理的先决条件。